Increasing nitroglycerin release from patches enables circumvention of early nitrate tolerance

Cardiovascular Drugs and Therapy

Volumn 12, Issue 2, 1998, Pages 217-224

  Reiniger, Günther ^a   Lehmann, Günter ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b NONE

Author keywords

Angina pectoris; Interval therapy; Nitroglycerin; Patch; Tolerance

Indexed keywords

GLYCERYL TRINITRATE; NITRATE;

ANGINA PECTORIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RELEASE; DRUG TOLERANCE; EXERCISE; HUMAN; LONG TERM CARE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT DEPRESSION; TRANSDERMAL DRUG ADMINISTRATION; WORKLOAD;

ADULT; BLOOD PRESSURE; CORONARY DISEASE; ELECTROCARDIOGRAPHY; EXERCISE; HALF-LIFE; HEMODYNAMIC PROCESSES; HUMANS; MALE; MYOCARDIAL ISCHEMIA; NITROGLYCERIN; PAIN; VASODILATOR AGENTS;

EID: 0031749720     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007791429640     Document Type: Article

References (31)

1. Müller P, Imhof PR, Burghart F, Chu LC, Gerardin A. Human pharmacological studies of a new transdermal system containing nitroglycerin. Eur J Clin Pharmacol 1982;22: 473-480.
2. Georgopoulos AJ, Markis A, Georgiadis H. Therapeutic efficacy of a new transdermal system containing nitroglycerin in patients with angina pectoris. Eur J Clin Pharmacol 1982;22:481-185.
3. Reichek N, Priest C, Zimrin D, Chandler T, Sutton MSJ. Antianginal effects of nitroglycerin patches. Am J Cardiol 1984;54:1-7.
4. Parker JO, Fung H-L. Transdermal nitroglycerin in angina pectoris. Eur J Clin Pharmacol 1984;54:471-476.
5. Crean PA, Ribeiro P, Crea F, Davies GJ, Ratcliffe D, Maseri A. Failure of transdermal nitroglycerin to improve chronic stable angina: A randomized, placebo-controlled, double-blind, crossover trial. Am Heart J 1984;108:1494-1500.
6. Reiniger G, Kraus F, Dirschinger J, Blasini R, Rudolph W. High-dose transdermal nitroglycerin treatment: Attenuation of action within 24 hours? Herz 1985;10:157-162.
7. Reiniger G, Rudolph W. Treatment of coronary artery disease with nitroglycerin patches: Response of the antiischemic efficacy during continuous use with a patch-free interval. Herz 1985;10:305-311.
8. Reiniger G, Menke G, Boertz A, Kraus F, Rudolph W. Interval treatment for an effective therapy of angina pectoris with transdermal nitroglycerin patches: Placebo-controlled study including determination of nitroglycerin plasma concentrations. Herz 1987;12:68-73.
9. Cowan JC, Bourke JP, Reid DS, Julian DG. Prevention of tolerance to nitroglycerin patches by overnight removal. Am J Cardiol 1987;60:271-275.
10. Luke R, Sharpe N, Coxon R. Transdermal nitroglycerin in angina pectoris: Efficacy of intermittent application. J Am Coll Cardiol 1987;10:642-646.
11. Schaer DH, Buff LA, Katz RJ. Sustained antianginal efficacy of transdermal nitroglycerin patches using an overnight 10-hour nitrate-free interval. Am J Cardiol 1988;61: 46-50.
12. Parker JO. Intermittent nitroglycerin therapy in the treatment of chronic stable angina pectoris. J Am Coll Cardiol 1989;13:794-795.
13. Lehmann G, Reiniger G, Wolf H, Beyerle A, Rudolph W. Anti-ischemic effects of first and second dose of 20 mg isosorbide dinitrate administered 5 hours apart: Attenuation of effects despite rising plasma concentrations. Cardiovasc Drugs Ther 1995;9:339-345.
14. Jaeger H, Lutz D, Michaelis K, Salama ZB. Determination of nitrates in plasma. Drugs 1987;33(Suppl. 4):9-22.
15. Elkayam U, Kulick D, McIntosh N, Roth A, Hsueh W. Rahimtoola SH. Incidence of early tolerance to hemodynamic effects of continuous infusion of nitroglycerin in patients with coronary artery disease and heart failure. Circulation 1987;76:577-584.
16. Zimrin D, Reichek N, Bogin KT, et al. Antianginal effects of intravenous nitroglycerin over 24 hours. Circulation 1988; 77:1376-1384.
17. Dupuis J, Lalonde G, Lemieux R, Rouleau JL. Tolerance to intravenous nitroglycerin in patients with congestive heart failure: Role of increased intravscular volume, neurohumoral actiavation, and lack of prevention with N-acetylcysteine. J Am Coll Cardiol 1990;16:923-931.
18. Thadani U, Manyari D, Parker JO, Fung HL. Tolerance to the circulatory effects of oral isosorbide dinitrate. Circulation 1980;61:526-535.
19. Blasini R, Froer KL, Blümel G, Rudolph W. Rapid attenuation of effects of isosorbide dinitrate during long-term treatment of chronic congestive heart failure. Herz 1982; 7:250-258.
20. Reiniger G, Blasini R, Brügmann U, Rudolph W. Tolerance development with respect to the anti-ischemic effects of isosorbide dinitrate administered regularly in multiple daily doses. Herz 1984;9:146-152.
21. Münzel T, Kurz S, Heitzer T, Harrison DG. New insights into mechanisms underlying nitrate tolerance. Am J Cardiol 1996;77:24C-30C.
22. Ignarro LJ, Lippton H, Edwards JC, et al. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: Evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther 1981;218:739-749.
23. Packer M, Lee WH, Kessler PD, Gottlieb SS, Medina N, Yushak M. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med 1987;317:799-804.
24. Parker JD, Farrell B, Fenton T, Cohanim M, Parker JO. Counter-regulatory responses to continuous and intermittent therapy with nitroglycerin. Circulation 1991;84: 2336-2345.
25. Boesgaard S, Enghusen Poulsen H, et al. Acute effects of nitroglycerin depend on both plasma and intracellular sulfhydryl compound levels in vivo. Effects of agents with different sulfhydryl-modulating properties. Circulation 1998; 87:547-553.
26. Waldman SA, Rapoport RM, Ginsburg R, Murad F. Desensitization to nitroglycerin in vascular smooth muscle in rat and human. Biochem Pharmacol 1986;35:3525-3531.
27. Blasini R, Reiniger G, Brügmann U, Rudolph W. Circumvention to tolerance development to isosorbide dinitrate through use of an interval regimen. Herz 1984;9:166-170.
28. Parker JO, Farrell B, Lahey KA, Moe G. Effect of intervals between doses on the development of tolerance to isosorbide dinitrate. N Engl J Med 1987;316:1440-1444.
29. Reiniger G, Lehmann G, Beyerle A, Wolf H, Rudolph W. Treatment of symptomatic and asymptomatic myocarilial ischemia during everyday activities with 120 mg isosorbide dinitrate in sustained-release form. Herz 1990;15:259-265.
30. Beyerle A, Reiniger G, Rudolph W. Long-acting, marked antiischemic effects maintained unattenuated during long-term interval treatment with once-daily isosorbide-5-mononitrate in sustained-release form. Am J Cardiol 1990;65: 1434-1437.
31. Parker JO, Amies MH, Hawkinson RW, et al. Intermittent transdermal nitroglycerin therapy in angina pectoris. Clinically effective without tolerance or rebound. Circulation 1995;91:1368-1374.